Futurewise Research, a leading market intelligence firm, has released an in-depth market report on the Immune Repertoire ...

Elekta (EKTA-B.ST) announced today that it has partnered with Azra AI, the industry’s only end-to-end oncology workflow automation platform, to enhance cancer registry operations through automation ...

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company ...

OncoZenge AB (publ) today announces its participation at the 2025 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting taking place in Seattle, USA, on June 26-28, 2025, where ...

Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis, when applied topically in an emollient cream. The researchers, whose study is published ...

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces the launch of PRE-CISE, a Eurostars-funded research collaboration with Danish PreTT and TetraKit ...

On Sunday, the UK marked Mother’s Day, and my social feeds were packed with posts – flowers, handmade cards, perfectly plated meals, and, of course, a wave of ads pushing pricey gifts. The marketing ...

Scientists have developed a new transgene control system that shows early promise for treating rare brain disorder Rett syndrome.

Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - March 2025 on 24 April, 2025. Interested parties may join the Company’s quarterly conference call on ...

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...

CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks ...

The Next-Generation Biomanufacturing market, valued at USD 25.10 billion in 2024, is expected to register robust revenue CAGR of 10.2%.Request free copy of this report: April, 2025 - Rising demand ...